Critical care and infectious disease specialist Innoviva Specialty Therapeutics Inc (IST), a subsidiary of Innoviva Inc (Nasdaq:INVA), revealed on Monday that it has secured exclusive US marketing rights to Zevtera (ceftobiprole) from Swiss biopharmaceutical R&D company Basilea Pharmaceutica Ltd (SIX:BSLN).
Zevtera is an advanced-generation cephalosporin antibiotic approved by the US Food and Drug Administration (FDA) for treating various bacterial infections, including MRSA.
Innoviva plans to commercialise Zevtera in the United States in mid-2025.
This acquisition strengthens Innoviva's product portfolio and expands its presence in the infectious disease market.
Eli Lilly and Co receives approval from FDA for Zepbound
NHS England rolls out Ultragenyx Pharmaceutical's Evkeeza for HoFH patients
PTC Therapeutics submits vatiquinone NDA to US FDA
Sapience Therapeutics' ST316 receives US FDA Orphan Drug Designation
Ionis Pharmaceuticals' TRYNGOLZA receives US FDA approval
Breckenridge Pharmaceutical launches FDA approved methadone injection
Mesoblast's Ryoncil receives FDA approval
Sensorion declares positive initial data in Audiogene gene therapy trial
Neurizon submits IND application for NUZ-001 to support HEALEY ALS platform trial